- \n
- Net Sales for the second quarter 2026 were $17.8 million, an increase over net sales for the first quarter 2026 and an 11% increase over the same period in 2025<\/i><\/li>\n
- Gross Profit for the second quarter 2026 increased 30% over the same period in 2025 and Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume<\/i><\/li>\n
- Generated $2.1 million of Cash Flow from Operations in the second quarter 2026, increasing cash position at June 30, 2026 to $24.8 million<\/i><\/li>\n
- On track to achieve full-year guidance with emphasis on top line growth, improving gross margins and positive cash flow<\/i><\/li>\n<\/ul>\n
WIXOM, Mich.–(BUSINESS WIRE<\/a>)–
\nRockwell Medical, Inc. (the “Company”) (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and six months ended June 30, 2026.<\/p>\nThis press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260813588314\/en\/<\/a><\/p>\n
![\"Rockwell](\"https:\/\/mms.businesswire.com\/media\/20260813588314\/en\/2874929\/4\/RockwellChart.jpg\")
<\/p>\nRockwell Medical’s Profitability Trend (2021-2026)<\/p>\n<\/div>\n
\n“The momentum in our business continues to build. Our second quarter results reflect the outcome of the actions we have taken to strengthen our commercial position, improve operational efficiency, and enhance profitability,” said Mark <\/a>Strobeck, Ph.D.<\/a>, Rockwell Medical\u2019s President and CEO. “We are a fundamentally stronger company today, with a growing customer base, improving margins, a solid cash position, and a clear path toward achieving our 2026 guidance. As we enter the second half of the year, we remain focused on executing our growth strategy, expanding profitability, generating positive cash flow, and delivering long-term value for shareholders.”<\/p>\n
FINANCIAL HIGHLIGHTS<\/b><\/p>\n
Net Sales<\/span><\/p>\n
- \n
- \nNet sales for the three months ended June 30, 2026 were $17.8 million, which represents an 11% increase over net sales of $16.1 million for the same period in 2025 primarily driven by additional sales to new customers in the Western United States and greater purchasing from our existing customers.<\/p>\n<\/li>\n
- \nNet sales for the six months ended June 30, 2026 were $35.1 million, representing a slight increase over the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Gross Profit<\/span><\/p>\n
- \n
- \nGross profit for the three months ended June 30, 2026 was $3.2 million, which represents an increase of 30% over $2.5 million for the same period in 2025 primarily driven by lower manufacturing costs and higher volume.<\/p>\n<\/li>\n
- \nGross profit for the six months ended June 30, 2026 was $6.1 million, which represents an 11% increase over the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Gross Margin<\/span><\/p>\n
- \n
- \nGross margin for the three months ended June 30, 2026 was 18%, up from 16% for the same period in 2025.<\/p>\n<\/li>\n
- \nGross margin for the six months ended June 30, 2026 was 17%, up from 16% for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Net Income (Loss)<\/span><\/p>\n
- \n
- \nNet loss for the three months ended June 30, 2026 was $1.2 million, which represents an improvement over a net loss of $1.5 million for the same period in 2025, and an improvement over a net loss of $1.6 million in the first quarter of 2026.<\/p>\n<\/li>\n
- \nNet loss for the six months ended June 30, 2026 was $2.8 million, which represents an improvement over a net loss of $3.0 million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Adjusted EBITDA<\/span><\/p>\n
- \n
- \nAdjusted EBITDA for the three months ended June 30, 2026 was ($0.2) million, which was in-line with Adjusted EBITDA of ($0.2) million for the same period in 2025.<\/p>\n<\/li>\n
- \nAdjusted EBITDA for the six months ended June 30, 2026 was ($0.4) million, which represents an improvement compared to Adjusted EBITDA of ($0.7) million for the same period in 2025.<\/p>\n<\/li>\n<\/ul>\n
Cash, Cash Equivalents and Investments Available-for-Sale<\/span><\/p>\n
- \n
- \nCash and cash equivalents and investments available-for-sale at June 30, 2026 was $24.8 million, which represents an increase over $23.9 million at the end of the first quarter 2026 and in line with the Company’s cash position at year-end 2025.<\/p>\n<\/li>\n<\/ul>\n
- Gross Profit for the second quarter 2026 increased 30% over the same period in 2025 and Gross Margin expanded to 18% primarily driven by lower manufacturing costs and higher volume<\/i><\/li>\n
![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20260813588314\/en\/2874929\/3\/RockwellChart.jpg\")
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260813588314\/en\/2874827\/3\/Rockwell_Medical_-_logo_-_BusinessWire.jpg\"){kind=logo}
<\/td>\n<\/tr>\n